颗粒细胞殖民地刺激因子药物和14种癌症风险目标的遗传变异:孟德尔随机化研究
Heran Zhou1, Siyi Yan, Junhua Guo
1Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Medicine
|October 25, 2025
概括
颗粒细胞殖民地刺激因子 (G-CSF) 药物可能会增加肺状细胞癌 (LUSC) 和潜在的雌激素受体阴性乳腺癌的风险. 需要进一步的研究来证实这些发现,并了解G-CSF的长期安全性.
科学领域:
- 在瘤学瘤学.
- 药物基因组学 药物基因组学
- 遗传流行病学遗传流行病学
背景情况:
- 在临床实践中使用花细胞殖民地刺激因子 (G-CSF).
- 之前的研究已经产生了关于G-CSF与癌症风险相关的有争议的结果.
- 调查G-CSF与各种癌症之间的潜在因果关系对于患者的安全至关重要.
研究的目的:
- 调查G-CSF与14种不同类型的癌症之间的潜在因果关系.
- 使用药物标的门德尔随机化方法来进行强大的因果推理.
- 评估基因代理G-CSF暴露与癌症风险之间的关联.
主要方法:
- 进行了一项针对药物的门德尔随机化研究.
- 数据来源于DrugBank,表达量特征位点 (eQTL) 基因联盟和FinnGen数据集.
- 采用了多种统计方法 (例如,逆方差加权,门德尔随机化-埃格尔) 和灵敏度分析,并对多次测试进行了邦费罗尼校正.
主要成果:
- 在基因代理的G-CSF暴露和肺状细胞癌 (LUSC) 的风险增加之间发现了显著的关联.
- 观察到与雌激素受体阴性乳腺癌的潜在关联.
- 对于其他12种癌症类型,没有发现显著的关联,敏感性分析证实没有显著的异质性或性.
结论:
- G-CSF可能在LUSC的发展和潜在的雌激素受体阴性乳腺癌中起因作用.
- 临床影响,特别是长期使用G-CSF的临床影响,需要谨慎解释.
- 进一步的大规模前性研究是必要的,以验证这些发现,并为G-CSF风险效益平衡的临床建议提供信息.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Mutagenicity and Carcinogenicity
1.9K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K
Differentiation of Common Myeloid Progenitor Cells
3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
Mismatch Repair
6.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K


